Onxeo SA (ONXEO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Onxeo SA (ONXEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8117
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Onxeo SA (Onxeo) is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer, among others. Onxeo’s livatag is a nanoparticle formulation of doxorubicin, which is developed for the treatment of primary liver cancer. The company provides preclinical and clinical development, regulatory affairs, and other services. It markets its products through its distribution network. Onxeo is headquartered in Paris, France.

Onxeo SA (ONXEO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onxeo SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Onxeo SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onxeo SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Onxeo Enters into Research Agreement with Royal College of Surgeons in Ireland 11
Onxeo Enters into Agreement with Centro de Investigacion Medica Aplicada 12
Onxeo Enters into Agreement with Croix-Rousse Hospital and Centre de Recherche en Cancerologie 13
Onxeo Enters into Agreement with Synovo 14
DARA BioSciences Enters into Commercialization Agreement with Onxeo 15
Licensing Agreements 16
SWK Holdings Receives Beleodaq Royalty Rights from Onxeo 16
Monopar Therapeutics Enters into Licensing Agreement with Onxeo 17
Pint Pharma Enters into Licensing Agreement with Onxeo for Beleodaq 18
Onxeo Enters into Licensing Agreement with Bruno Farmaceutici 19
Equity Offering 20
Onxeo to Raise USD6.3 Million in Equity Financing 20
Onxeo Raises USD16.7 Million in Private Placement of Shares 22
Onxeo Raises USD14 Million in Private Placement of Shares 23
Onxeo to Raise USD1 Million in Private Placement of Shares 24
Onxeo Raises USD51 Million in Rights Offering 25
Asset Transactions 27
Vectans Pharma to Acquire Sitavig and Loramyc from Onxeo 27
Acquisition 28
Onxeo Acquires DNA Therapeutics 28
Onxeo SA – Key Competitors 29
Onxeo SA – Key Employees 30
Onxeo SA – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 31
Recent Developments 33
Financial Announcements 33
Jul 27, 2018: Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook 33
May 16, 2018: Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information 36
Mar 29, 2018: Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update 37
Oct 26, 2017: Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information 40
Jul 28, 2017: Onxeo Reports First-Half 2017 Results and Business Update 41
Apr 26, 2017: Onxeo: Q1 2017 financial information and business update 43
Mar 07, 2017: Onxeo: Full-year 2016 Results and Outlook for 2017 44
Corporate Communications 46
Mar 01, 2017: Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development 46
Mar 01, 2017: Onxeo announces two new executive appointments 47
Legal and Regulatory 48
Jan 23, 2018: Onxeo Announces Update On Litigation with SpeBio/SpePharm 48
Product News 49
Oct 02, 2017: Onxeo Introduces platON, a Proprietary Chemistry Platform of Decoy Oligonucleotides 49
04/24/2017: Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma 50
03/31/2017: Spectrum Pharmaceuticals Highlights Two Abstracts on BELEODAQ (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington 51
03/21/2017: Onxeo to Present Data on Key Orphan Oncology Asset Beleodaq at AACR Annual Meeting 52
Other Significant Developments 53
Mar 14, 2018: Onxeo Provides Financial Update 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Onxeo SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onxeo SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onxeo SA, Deals By Therapy Area, 2012 to YTD 2018 9
Onxeo SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onxeo Enters into Research Agreement with Royal College of Surgeons in Ireland 11
Onxeo Enters into Agreement with Centro de Investigacion Medica Aplicada 12
Onxeo Enters into Agreement with Croix-Rousse Hospital and Centre de Recherche en Cancerologie 13
Onxeo Enters into Agreement with Synovo 14
DARA BioSciences Enters into Commercialization Agreement with Onxeo 15
SWK Holdings Receives Beleodaq Royalty Rights from Onxeo 16
Monopar Therapeutics Enters into Licensing Agreement with Onxeo 17
Pint Pharma Enters into Licensing Agreement with Onxeo for Beleodaq 18
Onxeo Enters into Licensing Agreement with Bruno Farmaceutici 19
Onxeo to Raise USD6.3 Million in Equity Financing 20
Onxeo Raises USD16.7 Million in Private Placement of Shares 22
Onxeo Raises USD14 Million in Private Placement of Shares 23
Onxeo to Raise USD1 Million in Private Placement of Shares 24
Onxeo Raises USD51 Million in Rights Offering 25
Vectans Pharma to Acquire Sitavig and Loramyc from Onxeo 27
Onxeo Acquires DNA Therapeutics 28
Onxeo SA, Key Competitors 29
Onxeo SA, Key Employees 30
Onxeo SA, Subsidiaries 31
Onxeo SA, Joint Venture 31

List of Figures
Onxeo SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onxeo SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Onxeo SA (ONXEO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsui Fudosan Co., Ltd.:戦略・SWOT・企業財務分析
    Mitsui Fudosan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Fudosan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Newfield Exploration Company:戦略・SWOT・企業財務分析
    Newfield Exploration Company - Strategy, SWOT and Corporate Finance Report Summary Newfield Exploration Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Leroy Seafood Group ASA:企業の戦略・SWOT・財務情報
    Leroy Seafood Group ASA - Strategy, SWOT and Corporate Finance Report Summary Leroy Seafood Group ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BTB Real Estate Investment Trust:企業の戦略・SWOT・財務分析
    BTB Real Estate Investment Trust - Strategy, SWOT and Corporate Finance Report Summary BTB Real Estate Investment Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Ra Medical Systems Inc (RMED):医療機器:M&Aディール及び事業提携情報
    Summary Ra Medical Systems Inc (Ra Medical Systems) is a medical device company that develops, designs, and commercializes excimer laser systems for the treatment of cardiovascular and dermatologic diseases. The company’s technology provides operational versatility and dose customization. Its produc …
  • Mabuhay Vinyl Corp (MVC):企業の財務・戦略的SWOT分析
    Mabuhay Vinyl Corp (MVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Parker Drilling Co (PKD):石油・ガス:M&Aディール及び事業提携情報
    Summary Parker Drilling Co (Parker) is a provider of drilling solutions to the energy industry. It offers services which include land drilling, barge drilling, well services, rig design, construction, operations and maintenance among others. The company provides offshore and onshore contract drillin …
  • NovoCure Ltd (NVCR):企業の製品パイプライン分析
    Summary NovoCure Ltd (NovoCure) develops and commercializes novel delivery systems for the treatment of cancers of brain, abdomen, and torso. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division solid tumor can …
  • Kancera AB (KAN):企業の財務・戦略的SWOT分析
    Summary Kancera AB (Kancera) is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping …
  • Carlisle Companies Incorporated:戦略・SWOT・企業財務分析
    Carlisle Companies Incorporated - Strategy, SWOT and Corporate Finance Report Summary Carlisle Companies Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Jacobs Engineering Group Inc (JEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Jacobs Engineering Group Inc (Jacobs) is a professional services company. It offers a diverse range of technical, professional, and construction services. The company's service portfolio includes project; process, scientific and specialty consulting; engineering and construction; and operati …
  • MediGene AG (MDG1):企業の財務・戦略的SWOT分析
    MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Indivumed GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Indivumed GmbH (Indivumed) is an oncology company that provides solutions for diagnosis and treatment of cancer. The company is involved in the generation, characterization, and analysis of biologic samples from human cancer patients. It offers biospecimen products and clinical data sets; an …
  • Cochin Shipyard Ltd (COCHINSHIP):企業の財務・戦略的SWOT分析
    Cochin Shipyard Ltd (COCHINSHIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • The Lubrizol Corp:企業の戦略的SWOT分析
    The Lubrizol Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • SciClone Pharmaceuticals Inc:企業の戦略的SWOT分析
    SciClone Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Somnomed Ltd (SOM)-医療機器分野:企業M&A・提携分析
    Summary Somnomed Ltd (SomnoMed) is medical device company that develops produces, commercializes and sells device for the oral treatment of sleep related disorders. The company’s products include somnodent, an oral appliance for obstructive sleep apnea; and somnobrux, a mouthguard that protects pati …
  • Rubicon Genomics Inc-医療機器分野:企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • Foundation for Innovative New Diagnostics-医療機器分野:企業M&A・提携分析
    Summary Foundation for Innovative New Diagnostics (FIND) is a non-profit organization that offers diagnostic tests. The organization develops and implements new diagnostic technologies for the development of diagnostic tests. Its services include diagnostic technologies development, quality-assured …
  • Neos Therapeutics Inc (NEOS):製薬・医療:M&Aディール及び事業提携情報
    Summary Neos Therapeutics Inc (Neos Therapeutics), formerly Neostx Inc, develops, manufactures, and commercializes branded pharmaceuticals. The company’s portfolio includes Adzenys XR-ODT that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients of six years …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆